Yune Kunes

Yune Kunes has extensive work experience in the pharmaceutical industry, particularly in analytical development and program management. They began their career at Millennium Pharmaceuticals in 1999 as a Sr. Scientist in antibody and small molecule drug discovery and development. In 2005, they joined AbbVie as an Associate Director in biologics CMC development and cell line development. They later worked at Shire as a Director in bioanalytical development from 2011 to 2015. Yune then served as VP and Head of Analytical Development and Senior Director of Program Management at Fortress Biotech from 2015 to 2018. They went on to become the VP of Analytical Development at TG Therapeutics from 2018 to 2022. Currently, Yune holds the position of VP and Head of Analytical Development, Formulation, and Early Stage QC at Prime Medicine, Inc. since 2022.

Yune Kunes holds a B. Eng. degree in Chemical Engineering and Applied Chemistry from Tsinghua University. Additionally, they have pursued a Ph.D. in Biochemistry at The Graduate Center, City University of New York. Following completion of their Ph.D., Yune Kunes went on to further their education by undertaking a postdoctoral position in Cell Biology at Harvard Medical School.